In the Industry
At Lyra, we are advancing leading-edge science to develop therapeutics that can make a positive impact on the lives of millions of patients.
Here are some of the ways we are making a difference for patients, for new therapeutic products, and for our community.
Lyra CMO Dr. Robert Kern and CEO Maria Palasis discuss the convergence of materials science, drug development and formulation chemistry that made possible LYR-210 and 220, in Drug Development & Delivery.
New, positive LYR-210 data from the LANTERN Phase 2 study of LYR-210 in chronic rhinosinusitis were the subject of two oral presentations at the Combined Otolaryngology Spring Meetings (COSM) 2022 with the SNOT-22 subdomain presentation selected as a top clinical abstract at the meeting.
Lyra’s LYR-210 Phase 2 data was selected to receive the Clinical Science Maurice Cottle Award honoring best clinical or basic science, named after the founder of the American Rhinologic Society, announced at the ARS Annual Meeting in Los Angeles on Saturday, October 1st.
New, positive LYR-210 data from the LANTERN 6-month post-treatment evaluation and recently completed pharmacokinetic study were the subject of two oral presentations at the 67th Annual Meeting of the American Rhinologic Society (ARS), October 2021, with the PK study selected as a top clinical abstract at the meeting.
Published in the International Forum of Allergy & Rhinology (IFAR): positive data from our LANTERN Ph2 study with LYR-210, in development as a non-invasive alternative to sinus surgery for patients with chronic rhinosinusitis.
Lyra CEO Maria Palasis was named an Extraordinary Women Advancing Healthcare 2021 winner by The Commonwealth Institute, honoring remarkable leaders shaping healthcare across Massachusetts.
Lyra CEO Maria Palasis was recognized as part of the 2021 Medical Marketing & Media Hall of Femme, highlighting standout woman healthcare executives in biopharma, med device/diagnostics, marketing/communications and media.
Lyra CMO Robert Kern, MD, discusses the positive LANTERN Phase 2 study results for LYR-210, offering hope for a new treatment option with up to 6 months of relief for Chronic Rhinosinusitis patients.
Drug Delivery Business took a dive into Lyra’s product approach for chronic rhinosinusitis, LYR-210 and the company’s platform for ENT and other chronic diseases.
On the MassDevice list of “8 drug delivery innovations you need to know,” Lyra was recognized as “looking to make waves in the ear, nose and throat (otolaryngology) disease treatment space with drugs administered through a bioresorbable polymeric matrix.”
We are pleased to welcome our new CMO, Robert Kern, MD, a renowned physician in the ENT field and a world-leading expert in chronic rhinosinusitis. Introduced in this Drug Delivery Business News article, Dr. Kern will oversee the development of Lyra’s clinical pipeline.
Lyra CEO Maria Palasis was elected into the National Academy of Engineering for outstanding contributions to the design of medical devices and drug delivery systems, including her work on LYR-210 and LYR-220.
Lyra CEO Maria Palasis hosted two networking sessions on Combination Products at the MedExecWomen Fall Forum, focused on advances in medtech and medical devices by women leaders.
Lyra is pleased to welcome Dr. Nancy Snyderman to the Board of Directors. An accomplished otolaryngologist and surgeon, she brings deep expertise that will be invaluable as we advance innovative treatments for ear, nose and throat diseases.
How can companies add more women in leadership roles? How can women pursue these positions? In a Q&A, CEO Maria Palasis discusses specific steps both can take to increase gender diversity in the workplace.
Lyra CEO Maria Palasis was one of three women leaders in life sciences discussing the current unique capital raising environment on a panel hosted by BioDirector.
The Lyra team participated in the Nasdaq virtual opening bell ringing ceremony to commemorate the company’s first week on the Nasdaq exchange as LYRA.
